Advertisements
 

The Salgi Esophageal Cancer Research Foundation Issues Esophageal Cancer Research Funding For the Second Time

December 14, 2018

The Salgi Esophageal Cancer Research Foundation has issued funding for esophageal cancer research in November, 2018; the second time in just seven years since the charity was founded.

The Foundation awarded principal investigator, Dr. Donald Low and Virginia Mason Medical Center, grant funding.  Dr. George Hanna of St Mary’s Hospital (Imperial College London) is co-investigator.

In 2011, The Salgi Esophageal Cancer Research Foundation was established to raise awareness, encourage early detection and to fund research of esophageal cancer.  Since 2011, the foundation has both raised awareness and encouraged the importance of earliest possible detection throughout New England, across the United States and internationally.  The Salgi Esophageal Cancer Research Foundation first funded esophageal cancer research in July, 2015.

“The Salgi Esophageal Cancer Research Foundation is excited to be a part of Dr. Low’s, Professor Hanna’s and Virginia Mason’s research efforts in honor of all the brave men and women who have been affected by esophageal cancer and to hopefully reduce incidence and improve outcomes for individuals in the future,” President of the foundation, stated.

The research intends to establish a non-invasive test for the detection of esophageal cancer that is based upon the unique signature of volatile organic compounds (VOCs) within exhaled breath and to analyze exhaled VOCs in response to therapeutic intervention in patients.

Learn the Facts About Esophageal Cancer

One of the primary risk factors associated with esophageal cancer is Gastroesophageal Reflux Disease, also known as GERD or acid reflux disease, of which the most common symptom is chronic heartburn.  Other risk factors include obesity, heavy drinking, poor nutrition and smoking and/or use of tobacco products.

With over a 733% increase in the past four decades, esophageal cancer is among the fastest growing and deadliest cancers in the United States and the western world.1

There are no current standard or routine screenings to detect esophageal cancer in its earlier stages. Current guidelines recommend referral for endoscopy “only in the setting of ‘red flag’ symptoms that are frequently associated with inoperable disease,” Dr. Low stated.

These ‘red flag’ symptoms, such as difficulty swallowing, typically appear once the cancer has become advanced.  This, in addition with other factors mentioned, leads to the current overall five-year survival rate of only 19.2%.2  Despite its rapid increase and poor prognosis, esophageal cancer receives very little awareness and research funding.

The Salgi Esophageal Cancer Research Foundation

The Salgi Foundation: Past Esophageal Cancer Research Funding

In July, 2015, the Salgi Esophageal Cancer Research Foundation issued esophageal cancer research funding to Program Director Dr. Carlos Minacapelli and Rutgers Robert Wood Johnston Medical School.  That research was presented as a poster presentation during Digestive Disease Week in May, 2017.

Thank you!

The Salgi Esophageal Cancer Research Foundation would like to thank all our supporters and donors who believe in this mission and who make these accomplishments possible.  However, this is just the beginning.  The Salgi Esophageal Cancer Research Foundation continuously receives many requests for esophageal cancer research.  We need to continue our efforts to fundraise so that we may continue to fulfill this mission to raise awareness, encourage early detection and fund research.

To make a tax-deductible donation to The Salgi Esophageal Cancer Research Foundation, please visit: SALGI.org/donate.

 

 

 

 

Sources:

1 “Esophageal Cancer Sees Dramatic Spike.” Gastroenterology and Endoscopy News. 18 October 2018. https://www.gastroendonews.com/In-the-News/Article/10-18/Esophageal-Cancer-Sees-Dramatic-Spike-/53083

2 “Cancer Stat Facts: Esophageal Cancer.” National Cancer Institute, Surveillance, Epidemiology, and End Results Program.  11 December 2018. https://seer.cancer.gov/statfacts/html/esoph.html

Advertisements

Foundation Reaches Milestone: Issues Esophageal Cancer Research Funding For the First Time.

July 28, 2015

The Salgi Esophageal Cancer Research Foundation has issued its first round of funding for esophageal cancer research earlier this month.

The foundation awarded program director, Dr. Carlos Minacapelli and Rutgers Robert Wood Johnston Medical School grant funding.

In 2011, The Salgi Esophageal Cancer Research Foundation was established to raise awareness, encourage early detection and to fund research of esophageal cancer.  Since 2011, the foundation has both raised awareness and encouraged the importance of earliest possible detection throughout New England, across the United States and internationally.

“The Salgi Esophageal Cancer Research Foundation is excited to be a part of Dr. Minacapelli’s and Rutger’s research efforts in honor of all the brave men and women who were affected by esophageal cancer and to hopefully reduce incidence and improve outcomes for individuals in the future” President of the foundation stated.

The Salgi Esophageal Cancer Research Foundation would like to thank all of our supporters and donors who believe in this mission and who make these accomplishments possible.  However, this is just the beginning.  We received many other research requests that we were unable to fund at this time.  We need to continue our efforts to fundraise so that we may continue to fund research.

Gastroesophageal Reflux Disease, also known as GERD or acid reflux disease, of which the most common symptom is chronic heartburn, is one of the primary risk factors associated with esophageal cancer.  Other risk factors include obesity, poor nutrition and smoking.  With over a 600% increase in the past decades, esophageal cancer is among the fastest growing and deadliest cancers in the United States and western world.

Currently, there are no standard or routine screenings to detect esophageal cancer in earlier stages. Symptoms, such as difficulty swallowing, typically appear once the cancer has become advanced and the overall five-year survival rate is only 17.5%.  Despite its rapid increase and poor prognosis, esophageal cancer receives very little awareness and research funding.

To make a tax-deductible donation to The Salgi Esophageal Cancer Research Foundation, please visit: SALGI.org/donate.

 


‘Jumping genes’ may drive esophageal cancer, Cancer Research UK

July 10, 2015

Cancer Research UK scientists have found that ‘jumping genes’ may add to the genetic chaos behind more than three-quarters of esophageal cancer cases, according to research published in BMC Genomics.

The scientists, from the University of Cambridge, used cutting-edge technology that can read DNA to study the genes of 43 esophageal tumour and blood samples to discover how much these mobile genetic sequences travel.

‘Jumping genes’, called L1 elements, can uproot themselves and move to new areas in the DNA, sometimes accidentally moving into genes that control the cell’s growth.

They found evidence that this happened around 100 times in each tumour sample, and in some tumours it happened 700 times.

esophageal cancer, esophageal, esophagus, esophagus cancer, research, cancer research, esophageal cancer research, esophagus cancer research, esophagus research, esophageal research, oesophageal cancer, oesophagus cancer, oesophageal cancer research, oesophagus cancer research, oesophageal research, oesophagus research, cancer charity, esophageal cancer charity, esophageal cancer nonprofit, esophageal cancer research charity, esophageal cancer research nonprofit, salgi esophageal cancer research foundation, the salgi esophageal cancer research foundation nonprofit charity

Image: Cancer Research UK

If a jumping gene lands in or near an important gene that controls cell growth, it can wreak havoc, changing how the gene works so that it inadvertently tells the cell to grow and divide out of control – which could lead to cancer.

Study author Dr Paul Edwards, at the Cancer Research UK Cambridge Institute, said: “These jumping genes play hopscotch across our genetic code in cancer cells more than in normal cells. When one of these mobile genetic sequences plants itself in the middle of a gene that controls the cell’s growth it radically alters how the cell behaves, which can sometimes cause cancer.

“Research has shown that this might also happen in lung and bowel cancers. So it’s vital we find out more about how the cells do this in a bid to find ways to treat these cancers.”

The research is part of the International Cancer Genome Consortium (ICGC) – a global project using the latest gene sequencing technology to reveal the genetic changes behind cancer.  The esophageal cancer project is funded by Cancer Research UK.

Dr Kat Arney, Cancer Research UK’s science information manager, said: “Esophageal cancer is one of the hardest cancers to treat, and we are committed to funding more research to find out its underlying causes. These new findings reveal more about the genetic chaos that underpins esophageal tumours, and could one day help us develop better ways to diagnose, treat and monitor the disease.”

References: Paterson et al. Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired end sequencing analysis. BMC Genomics. DOI: 10.1186/s12864-015-1685-z.

This post is based on materials provided by Cancer Research UK.